Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy.
- Resource Type
- Article
- Authors
- Harrysson, Sara; Eloranta, Sandra; Ekberg, Sara; Enblad, Gunilla; Andersson, Per-Ola; Sonnevi, Kristina; Ljungqvist, Maria; Sander, Birgitta; Jerkeman, Mats; Smedby, Karin E.
- Source
- Leukemia & Lymphoma. Apr2024, Vol. 65 Issue 4, p534-537. 4p.
- Subject
- *DIFFUSE large B-cell lymphomas
*T cells
- Language
- ISSN
- 1042-8194
This document discusses the outcomes for patients with secondary central nervous system (CNS) involvement in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and estimates their eligibility for CAR T-cell therapy. Secondary CNS lymphoma (SCNSL) is associated with poor survival, and there is currently no established standard therapy for this condition. The document presents a study that investigated the outcomes of 145 consecutive SCNSL patients treated in clinical routine and estimated the proportion and outcome of those who could potentially have been eligible for CAR T-cell therapy. The study found that only a small percentage of patients met the eligibility criteria for CAR T-cell therapy. The study suggests that alternative treatment options are needed for these high-risk patients, including CAR T-cell therapy. [Extracted from the article]